SSRI
Intercellular communication in the central nervous system requires the precise control of the duration and the intensity of neurotransmitter action at the specific receptors. After they have been released at the synapse, neurotransmitters activate pre- and/or postsynaptic receptors. To terminate synaptic transmission, neurotransmitters can, in turn, be inactivated by either enzymatic degradation or active transport into neuronal and/or glial cells by neurotransmitter transporters[1]. Reuptake inhibitors of neurotransmitters have a direct effect on extracellular concentrations of neurotransmitters in the synapses, and therefore influence neurotransmission. Axon Medchem offers inhibitors for a wide range of (monoamine) reuptake inhibitors of high quality.
[1] Neurotransmitter Transporters in the Central Nervous System. J. Masson, C. Sagné, M. Hamon, S. El Mestikawy. Pharm. Rev. 1999, 51, 439-464.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1462 | Azaphen | Antidepressant | €105.00 | |
1257 | BTS 54-505 | 5-HT uptake inhibitor | €85.00 | |
1320 | Citalopram hydrobromide | SSRI; Antidepressant | €75.00 | |
3315 | Escitalopram oxalate | SSRI; Antidepressant | €50.00 | |
1302 | Fluoxetine hydrochloride | SSRI | €75.00 | |
1556 | Fluvoxamine maleate | SSRI | €50.00 | |
1139 | LY 393558 | SSRI; 5-HT1B and 5-HT1D antagonist | €125.00 | |
1452 | Paroxetine hydrochloride | SSRI | €75.00 | |
1300 | Sertraline hydrochloride | SSRI; Antidepressant | €85.00 |